Investigational drug · Phase 2
EPI-001
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Androgenetic Alopecia.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "EPI-001"
First trial start
2026
Jan 12, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "EPI-001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Androgenetic Alopecia
Approved drugs for the same conditions: Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "EPI-001" as an intervention, largest first.
EpibiotechIndustry
NCT07618195 · 42 participants (planned) · Start Jan 12, 2026 · Primary completion Jun 1, 2028
Drug: EPI-001 · For: Androgenetic Alopecia
Sites: Seoul, South Korea
Newest research
PubMed records naming it or its code names, newest first.
- In silico study of androgen receptor N-terminal domain and exploration of its modulators.
Zhang W, Hu H, Zhu Y, et al. · J Biomol Struct Dyn 2025
- Ion mobility mass spectrometry unveils conformational effects of drug lead EPI-001 on the intrinsically disordered N-terminal domain of the androgen receptor.
Ahmed IMM, Rofe A, Henry MC, et al. · Protein Sci 2025
- A study of the role of androgen receptor and androgen receptor variant 7 in TNBC patients and the effect of their targeting by Enzalutamide and EPI-001 in MDA-MB-231.
Ali BM, El-Abhar HS, Mohamed G, et al. · J Steroid Biochem Mol Biol 2025
- Hybrid Androgen Receptor Inhibitors Outperform Enzalutamide and EPI-001 in inߕvitro Models of Prostate Cancer Drug Resistance.
Nicolescu RCB, Maylin ZR, Pérez-Areales FJ, et al. · ChemMedChem 2023
- Amelioration of Hepatic Steatosis by the Androgen Receptor Inhibitor EPI-001 in Mice and Human Hepatic Cells Is Associated with the Inhibition of CYP2E1.
Wang S, Li X, Xu W, et al. · Int J Mol Sci 2022
- Topological dynamics of an intrinsically disordered N-terminal domain of the human androgen receptor.
Sheikhhassani V, Scalvini B, Ng J, et al. · Protein Sci 2022
Also in development for Androgenetic Alopecia
- VDPHL01Phase 34 trials
Veradermics, Inc. · Androgenetic Alopecia, AGA, Male Pattern Baldness
- PP405 0.05%PP405Phase 33 trials
Pelage Pharmaceuticals, Inc. · Androgenetic Alopecia
- DA-001Phase 31 trial
Applied Biology, Inc. · Telogen Effluvium, Female Pattern Hair Loss, Female Pattern Hair Loss, Androgenic Alopecia
- SecretomeConditioned, Umbilical Cord Mesenchymal Stem Cells derived ConditionedPhase 24 trials
PT. Prodia Stem Cell Indonesia · Acute Respiratory Distress Syndrome, Androgenetic Alopecia, Ischemic Stroke
- AD-3031Phase 21 trial
Moogene Medi Co., Ltd · Androgenetic Alopecia
- AD-303APhase 21 trial
Moogene Medi Co., Ltd · Androgenetic Alopecia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.